NCT02293954 - Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2015

Primary Completion Date

March 6, 2022

Study Completion Date

September 11, 2025

Conditions

Breast CancerColon CancerExtrahepatic Bile Duct CancerGallbladder CancerGastrointestinal CancerLiver and Intrahepatic Biliary Tract CancerLung CancerMetastatic CancerPancreatic CancerRectal CancerThyroid Gland Medullary CarcinomaUnspecified Adult Solid Tumor, Protocol Specific

Interventions

PROCEDURE

radionuclide imaging

Given copper Cu 64 anti-CEA monoclonal antibody M5A IV

PROCEDURE

positron emission tomography

Undergo PET

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

DRUG

Cu 64 anti-CEA monoclonal antibody M5A IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER